Indical Medsurg Profile
Key Indicators
- Authorised Capital ₹ 11.00 Cr
as on 17-12-2024
- Paid Up Capital ₹ 9.18 Cr
as on 17-12-2024
- Company Age 12 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 1.95 Cr
as on 17-12-2024
- Revenue 412.09%
(FY 2021)
- Profit 775.63%
(FY 2021)
- Ebitda 740.74%
(FY 2021)
- Net Worth 20.61%
(FY 2021)
- Total Assets -36.20%
(FY 2021)
About Indical Medsurg
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 11.00 Cr and a paid-up capital of Rs 9.18 Cr.
The company has closed loans amounting to ₹1.95 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Partha Khanolkar, Yatin Rane, and Poorva Arolkar serve as directors at the Company.
- CIN/LLPIN
U33110MH2012PTC226911
- Company No.
226911
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
14 Feb 2012
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Indical Medsurg?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Poorva Arolkar  | Director | 24-Sep-2021 | Current |
| Partha Khanolkar | Director | 08-Aug-2017 | Current |
| Yatin Rane | Director | 29-Mar-2014 | Current |
Financial Performance of Indical Medsurg.
Indical Medsurg Private Limited, for the financial year ended 2021, experienced significant growth in revenue, with a 412.09% increase. The company also saw a substantial improvement in profitability, with a 775.63% increase in profit. The company's net worth Soared by an impressive increase of 20.61%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Indical Medsurg?
In 2021, Indical Medsurg had a promoter holding of 58.04% and a public holding of 41.96%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Interventional Cardiology Devices Disposables & Innovations Systems Private LimitedActive 17 years 3 monthsPartha Khanolkar is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 28 Apr 2021 | ₹9.50 M | Satisfied |
Others Creation Date: 31 Aug 2017 | ₹1.00 Cr | Satisfied |
How Many Employees Work at Indical Medsurg?
Unlock and access historical data on people associated with Indical Medsurg, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Indical Medsurg, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Indical Medsurg's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
